Babak Vakili, MD
Urogynecology and Reconstructive Pelvic Surgery · Madison, WINPI 1184705501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Caldera Medical, Inc at 30.1% of the total. Reporting peaked in 2024 at $1,244 and has fallen 79.1% since, to $260 in 2025.
Across 185 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$2K
- Medtronic$838
- Coloplast$805
- Boston Scientific$418
- Astellas Pharma US Inc$356
- Sumitomo Pharma America, Inc.$204
- plus $1K from 15 others
Across 10 payments — averaging $700.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$7K
What the payments were for
- Travel & lodging$551%
- Food & beverage$5,15894%
- Education$1152%
- Gifts$1423%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 31 | $1,651 |
| Medtronic | 15 | $838 |
| Coloplast | 23 | $805 |
| Boston Scientific | 12 | $418 |
| Astellas Pharma US Inc | 23 | $356 |
| Sumitomo Pharma America, Inc. | 14 | $204 |
| AbbVie | 8 | $195 |
| Pfizer | 12 | $187 |
| Axonics, Inc. | 7 | $161 |
| Urovant Sciences Inc | 11 | $154 |
| Mission Pharmacal Company | 9 | $151 |
| Therapeuticsmd, Inc. | 4 | $88 |
| Millicent US Inc | 5 | $77 |
| Bluewind Medical | 2 | $39 |
| Dentsply IH Inc. | 2 | $29 |
| Bard Peripheral Vascular, Inc. | 1 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Abbott | 1 | $23 |
| Duchesnay USA Incorporated | 1 | $21 |
| 180 Medical, Inc. | 1 | $17 |
| Provepharm Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,485 in reported general payments places this provider in the 70th percentile of 25 urogynecology and reconstructive pelvic surgery providers in Wisconsin.
See all urogynecology and reconstructive pelvic surgery providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 116 | $67,134 |
| GemtesaVibegron | 56 | $46,812 |
| Estradiol | 57 | $3,827 |
| Methenamine Hippurate | 28 | $2,481 |
| Solifenacin Succinate | 58 | $2,389 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 15 | $1,666 |
| Oxybutynin Chloride ErOxybutynin Chloride | 35 | $578 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 46 | $503 |
| Cephalexin | 30 | $141 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 48 | $111 |
| Cyclobenzaprine Hcl | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $356 | $67,134116 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $204 | $46,81256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 25 urogynecology and reconstructive pelvic surgery providers in Wisconsin.
Other urogynecology and reconstructive pelvic surgery in Madison
- Jon PennycuffMadison$58K
- Frank LinMadison$5K
- Margaret WilkesMadison$3K
- Sarah McAchranMadison$656
- Caroline CoxMadison$183
- Amy VidalinMadison$101
- Dobie GilesMadison$41
- Dennis MillerGermantown$31K
- Vini KonowitzGermantown$17K
- Sarit Aschkenazi SteinbergOconomowoc$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.